Incorporating innovative B-cell targeting therapeutics into a combined-modality bridging approach followed by timely consolidative haploidentical transplantation to salvage a pediatric patient with relapsed/refractory diffuse large B-cell lymphoma

被引：0
|
作者：
Chao, Yu-Ju [1 ]
Lee, Pei-Ing [2 ]
Yang, Tzu-Hsien [3 ]
Fang, Li-Hua [4 ]
Tsai, Yu-Chun [5 ]
Lee, Ming-Yuan [6 ]
Wang, Yun-Hsin [7 ]
Chen, Liuh-Yow [3 ]
Chen, Rong-Long [1 ]
机构：
[1] Koo Fdn Sun Yat Sen Canc Ctr, Dept Pediat Hematol & Oncol, Taipei, Taiwan
[2] Koo Fdn Sun Yat Sen Canc Ctr, Dept Nucl Med, Taipei, Taiwan
[3] Acad Sinica, Inst Mol Biol, Taipei, Taiwan
[4] Koo Fdn Sun Yat Sen Canc Ctr, Dept Pharm, Taipei, Taiwan
[5] Koo Fdn Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Taipei, Taiwan
[6] Koo Fdn Sun Yat Sen Canc Ctr, Dept Pathol, Taipei, Taiwan
[7] Koo Fdn Sun Yat Sen Canc Ctr, Dept Mol Med, Taipei, Taiwan
来源：
PEDIATRIC BLOOD & CANCER | 2024年
关键词：
NON-HODGKIN-LYMPHOMA; CHILDREN; CHEMOTHERAPY; ADOLESCENTS; RITUXIMAB; THERAPY; SCT;
D O I：
10.1002/pbc.31289
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
    van Imhoff, Gustaaf W.
    McMillan, Andrew
    Matasar, Matthew J.
    Radford, John
    Ardeshna, Kirit M.
    Kuliczkowski, Kazimierz
    Kim, WonSeog
    Hong, Xiaonan
    Goerloev, Jette Soenderskov
    Davies, Andrew
    Caballero Barrigon, Maria Dolores
    Ogura, Michinori
    Leppa, Sirpa
    Fennessy, Michael
    Liao, Qiming
    van der Holt, Bronno
    Lisby, Steen
    Hagenbeek, Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (05) : 544 - +
  • [32] Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
    Maziarz, Richard T.
    Zhang, Jie
    Yang, Hongbo
    Chai, Xinglei
    Yuan, Chengbo
    Schwarz, Elisabeth
    Jakovac, Mihael
    Martinez-Prieto, Marcela
    Agarwal, Abhijit
    Degtyarev, Evgeny
    Tam, Constantine
    Salles, Gilles
    BLOOD ADVANCES, 2022, 6 (08) : 2536 - 2547
  • [33] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
    Furqan, Fateeha
    Hamadani, Mehdi
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [34] How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma
    Wallace, Danielle S.
    Loh, Kah Poh
    Casulo, Carla
    BLOOD, 2025, 145 (03) : 277 - 289
  • [35] Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma
    Izutsu, Koji
    Kumode, Takahiro
    Yuda, Junichiro
    Nagai, Hirokazu
    Mishima, Yuko
    Suehiro, Youko
    Yamamoto, Kazuhito
    Fujisaki, Tomoaki
    Ishitsuka, Kenji
    Ishizawa, Kenichi
    Ikezoe, Takayuki
    Nishikori, Momoko
    Akahane, Daigo
    Fujita, Jiro
    Dinh, Minh
    Soong, David
    Noguchi, Hidehisa
    Buchbjerg, Jeppe Klint
    Favaro, Elena
    Fukuhara, Noriko
    CANCER SCIENCE, 2023, 114 (12) : 4643 - 4653
  • [36] Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma
    Wang, Tao
    Gao, Lei
    Wang, Yujie
    Zhu, Wenjun
    Xu, Lili
    Wang, Yang
    Yue, Wenqin
    Tang, Gusheng
    Chen, Li
    Chen, Jie
    Zhang, Weiping
    Yu, Xuejun
    Feng, Dongge
    Yang, Jianmin
    IMMUNOTHERAPY, 2020, 12 (13) : 997 - 1006
  • [37] Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
    Gisselbrecht, Christian
    Glass, Bertram
    Mounier, Nicolas
    Gill, Devinder Singh
    Linch, David C.
    Trneny, Marek
    Bosly, Andre
    Ketterer, Nicolas
    Shpilberg, Ofer
    Hagberg, Hans
    Ma, David
    Briere, Josette
    Moskowitz, Craig H.
    Schmitz, Norbert
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4184 - 4190
  • [38] A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma
    Brooks, Taylor R.
    Caimi, Paolo F.
    BLOOD REVIEWS, 2024, 63
  • [39] FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Kasamon, Yvette L.
    Price, Lauren S. L.
    Okusanya, Olanrewaju O.
    Richardson, Nicholas C.
    Li, Ruo-Jing
    Ma, Lian
    Wu, Yu-Te
    Theoret, Marc
    Pazdur, Richard
    Gormley, Nicole J.
    ONCOLOGIST, 2021, 26 (10) : 879 - 886
  • [40] Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
    Boonlerd, Pattamaporn
    Tantiworawit, Adisak
    Norasetthada, Lalita
    Chai-Adisaksopha, Chatree
    Punnachet, Teerachat
    Hantrakun, Nonthakorn
    Piriyakhuntorn, Pokpong
    Rattanathammethee, Thanawat
    Hantrakool, Sasinee
    Rattarittamrong, Ekarat
    ANNALS OF MEDICINE, 2023, 55 (02)
12345